New MS Vaccine Shows Promise

shutterstock_128456363Researchers from Baylor Institute for Immunology Research (BIIR) are looking into a potential vaccine that may show promise in treating or preventing multiple sclerosis. If the findings come out as expected, this may well be a significant first since it may be able to target MS early and preserve the immune system from doing much damage.

The study was launched 3 years ago and has recently been showing some promising findings with regards to finding a potential MS vaccine. Various insights from previous dendritic cell studies helped the researchers take a radically different approach to treating multiple sclerosis. Previous research has led researchers to identify a special property in dendritic cells that can influence how the immune system behaves. This property can play a big role in treating autoimmune diseases such as multiple sclerosis.

According to Dr. SangKon Oh, PhD, lead investigator of the said study, “We discovered that DC-ASGPR, one of the receptors expressed on human dendritic cells, has novel functions to promote antigen-specific regulatory T cells that can efficiently suppress inflammatory responses. This prompted us to test our discovery in autoimmune diseases where antigens are known.”

The early findings may indicate a clue on how this can lead to the potential development of MS vaccines. According to Dr. Oh, certain results have so far been positive that they are already planning a possible Phase I clinical trial in the next three years. Multiple sclerosis has no cure to date. A possible vaccine that can help prevent the disease from progressing early may be a promising approach to reducing the number of people affected by MS.

Source: Baylor Scott & White Health. “Promising results obtained with multiple sclerosis vaccine.” ScienceDaily. ScienceDaily, 23 September 2014. <www.sciencedaily.com/releases/2014/09/140923152106.htm>.

 
Both comments and pings are currently closed.